JP2024520912A - １日１回（ｑｄ）の吸入による投与のためのタクロリムスの乾燥粉末製剤 - Google Patents

１日１回（ｑｄ）の吸入による投与のためのタクロリムスの乾燥粉末製剤 Download PDF

Info

Publication number
JP2024520912A
JP2024520912A JP2023569859A JP2023569859A JP2024520912A JP 2024520912 A JP2024520912 A JP 2024520912A JP 2023569859 A JP2023569859 A JP 2023569859A JP 2023569859 A JP2023569859 A JP 2023569859A JP 2024520912 A JP2024520912 A JP 2024520912A
Authority
JP
Japan
Prior art keywords
tacrolimus
dose
composition
patient
inhaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520912A5 (https=
Inventor
デイル ジェイ． クリステンセン
クリストファー エス． クリーン
ジョン ジェイ． コレング
Original Assignee
ティーエフエフ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ティーエフエフ ファーマシューティカルズ インコーポレイテッド filed Critical ティーエフエフ ファーマシューティカルズ インコーポレイテッド
Publication of JP2024520912A publication Critical patent/JP2024520912A/ja
Publication of JP2024520912A5 publication Critical patent/JP2024520912A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023569859A 2021-05-12 2022-05-12 １日１回（ｑｄ）の吸入による投与のためのタクロリムスの乾燥粉末製剤 Pending JP2024520912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187774P 2021-05-12 2021-05-12
US63/187,774 2021-05-12
PCT/US2022/028972 WO2022241105A1 (en) 2021-05-12 2022-05-12 Dry powder formulations of tacrolimus for administration by inhalation once daily (qd)

Publications (2)

Publication Number Publication Date
JP2024520912A true JP2024520912A (ja) 2024-05-27
JP2024520912A5 JP2024520912A5 (https=) 2025-05-16

Family

ID=81928015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569859A Pending JP2024520912A (ja) 2021-05-12 2022-05-12 １日１回（ｑｄ）の吸入による投与のためのタクロリムスの乾燥粉末製剤

Country Status (7)

Country Link
US (1) US20220362222A1 (https=)
EP (1) EP4337173A1 (https=)
JP (1) JP2024520912A (https=)
CN (1) CN117750945A (https=)
AU (1) AU2022271790A1 (https=)
CA (1) CA3219943A1 (https=)
WO (1) WO2022241105A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118948810A (zh) * 2024-07-26 2024-11-15 四川大学 一种吸入式的mPEG-PLGA/FK506载药纳米颗粒及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
AU2009214443B2 (en) 2008-02-13 2013-10-10 Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
WO2011163600A2 (en) * 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration

Also Published As

Publication number Publication date
AU2022271790A1 (en) 2023-11-23
EP4337173A1 (en) 2024-03-20
WO2022241105A1 (en) 2022-11-17
US20220362222A1 (en) 2022-11-17
CA3219943A1 (en) 2022-11-17
CN117750945A (zh) 2024-03-22

Similar Documents

Publication Publication Date Title
AU2023251480B2 (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
US11452718B2 (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2020201557B2 (en) Aerosol pirfenidone and pyridone analog compounds
JP2025108419A (ja) エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
JP2020023537A (ja) Ｃｏｐｄの治療のためのチオトロピウムブロミド、フォルモテロール及びブデソニドの組み合わせ
CN120265283A (zh) (-)-表没食子儿茶素没食子酸酯类化合物的应用
JP2024520912A (ja) １日１回（ｑｄ）の吸入による投与のためのタクロリムスの乾燥粉末製剤
WO2026061535A1 (zh) 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途以及肺动脉高压的治疗方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250508

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260423